A survey suggests drug firms need to better inform consumers about nonsteroidal anti-inflammatory drugs' potential risks and could tap into a sales growth driver in a sizeable group of consumers who are ignoring their pain.
The research by consultancy Kelton Global for pharmaceutical NSAID marketer Iroko Pharmaceuticals LLC found that 61% of US consumers...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?